Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Palonosetron

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: Palonosetron. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-000298-23 Sponsor Protocol Number: PALO-04-07 Start Date*: 2005-07-19
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A Randomized, Double-blind, Multicenter, Parallel Group, Balanced, Stratified Phase 3 Study to Evaluate the Efficacy and the Safety of Single IV Doses of Palonosetron 0.025 mg, 0.050 mg, and 0.075 ...
    Medical condition: Postoperative nausea and vomiting.
    Disease: Version SOC Term Classification Code Term Level
    10054133 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022223-29 Sponsor Protocol Number: PALO-10-01 Start Date*: 2011-03-23
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Single-dose, multicenter, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of oral palonosetron 0.50 mg compared to I.V. palonosetron 0.25 mg administe...
    Medical condition: Nausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10054133 Prophylaxis of nausea and vomiting LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) PL (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-016775-30 Sponsor Protocol Number: NETU-08-18 Start Date*: 2011-02-24
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A phase III multicenter, randomized, double-blind, double-dummy, active-controlled, parallel group study of the efficacy and safety of oral netupitant administered in combination with palonosetron ...
    Medical condition: Nausea and vomiting in cancer patients receiving moderately emetogenic theraphy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000137-37 Sponsor Protocol Number: PALO-03-13 Start Date*: 2005-09-23
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Single Dose, Randomized, Double-Blind, Parallel Group, Multicenter Study of Palonosetron 0.25 mg, 0.50 mg and 0.75 mg Administered by the Oral Route versus Palonosetron 0.25 mg IV for the Preventio...
    Medical condition: Moderately emetogenic chemotherapy induced nausea and vomiting
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-023297-39 Sponsor Protocol Number: NETU-10-29 Start Date*: 2011-05-27
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A phase III, multicenter, randomized, double-blind, unbalanced (3:1) active control study to assess the safety and describe the efficacy of netupitant and palonosetron for the prevention of chemoth...
    Medical condition: Nausea and vomiting in cancer patients associated with chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-004853-27 Sponsor Protocol Number: Palonosetron Start Date*: 2007-09-05
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: A phase IV monocentre study to evaluate palonosetron in nausea/vomiting prevention in patients with breast or colon cancer, treated with moderately aemotogenic chemotherapic agents
    Medical condition: nausea and vomiting prevention
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054133 Prophylaxis of nausea and vomiting LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007827-14 Sponsor Protocol Number: PALO-08-09 Start Date*: 2009-11-24
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Multicenter, Phase IV, Open-Label, Uncontrolled Study to Assess the Efficacy and Safety of a Single Intravenous Dose of Palonosetron 0.25 mg (Aloxi®, Onicit®, Paloxi®) in the Prevention of Chemothe...
    Medical condition: Prevention of moderately emetogenic CINV in up to four repeated and consecutive single-day MEC cycles administered to patients with Non-Hodgkin’s Lymphomas.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003730-20 Sponsor Protocol Number: NEPA-15-31 Start Date*: 2020-09-17
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A multicenter, multinational, randomized, double-blind, pharmacokinetic and pharmacodynamic (PK/PD) dose-finding study of oral netupitant administered concomitantly with oral palonosetron in pediat...
    Medical condition: nausea and vomiting associating with emetogenic chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10047700 Vomiting PT
    20.0 10017947 - Gastrointestinal disorders 10028813 Nausea PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-003189-33 Sponsor Protocol Number: NHLPal Start Date*: 2006-10-31
    Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
    Full Title: Phase II study with Palonosetron alone in preventing chemotherapy-induced nausea and vomiting in untreated patients with aggressive Non Hodgkin’s Lymphomas who underwent moderately emetogenic chemo...
    Medical condition: preventing chemotherapy-induced nausea and vomiting in untreated patients with aggressive Non Hodgkin’s Lymphomas who underwent moderately emetogenic chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028817 Nausea and vomiting symptoms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002641-39 Sponsor Protocol Number: PALO-05-01 Start Date*: 2006-10-17
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Open-Label Pilot Study to Evaluate the Efficacy of Palonosetron Associated with Aprepitant (Emend) and Dexamethasone in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy (HEC)
    Medical condition: This is a Phase 4, open-label, pilot study to evaluate the Efficacy of Plaonosetron associated with Aprepitant (Emend) and Dexamethasone in preventing nausea and vomitting in chemotherapy-naïve pat...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001944-21 Sponsor Protocol Number: PALO-03-14 Start Date*: 2005-09-23
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Multicenter, Phase III, Open-Label, Uncontrolled Study to Assess the Safety and Efficacy of a Single Oral Dose of Palonosetron 0.75 mg in the Prevention of Chemotherapy Induced Nausea and Vomiting ...
    Medical condition: Moderately emetogenic chemotherapy induced nausea and vomiting
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-002643-89 Sponsor Protocol Number: PALO-05-02 Start Date*: 2005-12-14
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Double-blind Study to Compare the Efficacy of Palonosetron with or without the use of Dexamethasone on Days 2 and 3, in the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemot...
    Medical condition: This is a non-inferiority study in chemotherapy-naïve female patients with breast cancer, age 18 years or older, who are scheduled to receive Moderately Emetogenic Chemotherapy (MEC).
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003823-36 Sponsor Protocol Number: AS/PALO/002 Start Date*: 2011-11-08
    Sponsor Name:ASSOCIAZIONE SALENTINA ANGELA SERRA ONLUS
    Full Title: Phase II randomized multicenter study of multiple doses of palonosetron plus aprepitant versus multiple doses of palonosetron alone in preventing chemotherapy-induced nausea and vomiting in patient...
    Medical condition: patients with Acute Myeloid leukemia or high-risk Myelodisplastic syndrome according to IPSS score treated with AML-like multiple days chemotherapy regimen
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001747-37 Sponsor Protocol Number: PALO-15-17 Start Date*: 2015-07-28
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A phase 3, single-dose, multicenter, randomized, double-blind, parallel group study to assess the efficacy and safety of palonosetron 0.25 mg administered as a 30-minute IV infusion compared to pal...
    Medical condition: nausea and vomiting in cancer patients receiving highly emetogenic therapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10036899 Prophylaxis against chemotherapy induced vomiting LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-005803-33 Sponsor Protocol Number: TH06-001 Start Date*: 2007-01-18
    Sponsor Name:THERABEL LUCIEN PHARMA
    Full Title: ÉTUDE PILOTE OBSERVATIONNELLE CHEZ DES PATIENTES SOUFFRANT D’UN CANCER DU SEIN ET RECEVANT UNE CHIMIOTHÉRAPIE ÉMÉTISANTE TRAITÉES PAR UNE DOSE UNIQUE DE ALOXI® (PALONOSÉTRON) 0,25 MG ASSOCIÉE À UNE...
    Medical condition: The prevention of acute or delayed Chemotherapy-Induced Nausea and Vomiting (CINV) by the combination of palonosetron 250 microgrammes and methylprednisolone 80 mg in patients receiving a first adm...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10056989 Nausea post chemotherapy LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003956-32 Sponsor Protocol Number: POSTPAL Start Date*: 2016-03-15
    Sponsor Name:Umeå University
    Full Title: Effects of postoperative palonosetron in ambulatory patients identified with high risk for postdischarge nausea and vomiting (PDNV) – a randomized controlled trial with comparison to placebo.
    Medical condition: Nausea and vomiting in the home (after discharge) after day-case surgery under general anesthesia-
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004856 10028817 Nausea and vomiting symptoms HLT
    18.1 100000004863 10036285 Postoperative nausea LLT
    18.1 100000004865 10036901 Prophylaxis against postoperative nausea and vomiting LLT
    18.1 100000004865 10054182 Perioperative nausea and vomiting prophylaxis LLT
    18.1 100000004863 10028818 Nausea postoperative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022872-30 Sponsor Protocol Number: PALO-10-20 Start Date*: 2011-08-04
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatr...
    Medical condition: Study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10049091 Chemotherapy antiemetic prophylaxis LLT
    13.1 10042613 - Surgical and medical procedures 10036899 Prophylaxis against chemotherapy induced vomiting LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) AT (Completed) BG (Completed) EE (Completed) DE (Completed) FR (Ongoing) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-022971-79 Sponsor Protocol Number: PALO-10-14 Start Date*: 2011-05-23
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondan...
    Medical condition: Postoperative nausea and vomiting (PONV)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022117 - Injury, poisoning and procedural complications 10036238 Postoperative vomiting LLT
    14.0 10022117 - Injury, poisoning and procedural complications 10036285 Postoperative nausea LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-002935-25 Sponsor Protocol Number: 2609 Start Date*: 2006-06-27
    Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE
    Full Title: multicenter phase II study to evaluate palonosetron +desametasone in the prevention of nausea and vomiting in patientes resected for colon cancer and treated with moderate emetogenus chemotherapy.
    Medical condition: patientes resected for colon cancer and treated with moderate emetogenus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009944 Colon cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001800-74 Sponsor Protocol Number: NEPA-15-18 Start Date*: 2015-08-17
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A phase 3, multicenter, randomized, double-blind, active control study to evaluate the safety and efficacy of IV pro-netupitant/palonosetron (260 mg/0.25 mg) combination for the prevention of chemo...
    Medical condition: nausea and vomiting in cancer patients receiving highly emetogenic therapy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10036899 Prophylaxis against chemotherapy induced vomiting LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) CZ (Completed) ES (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 11:47:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA